|
1
|
Fuja DG, Rainusso NC, Shuck RL,
Kurenbekova L, Donehower LA and Yustein JT: Transglutaminase-2
promotes metastatic and stem-like phenotypes in osteosarcoma. Am J
Cancer Res. 8:1752–1763. 2018.PubMed/NCBI
|
|
2
|
Abarrategi A, Tornin J, Martinez-Cruzado
L, Hamilton A, Martinez-Campos E, Rodrigo JP, González MV, Baldini
N, Garcia-Castro J and Rodriguez R: Osteosarcoma: Cells-of-Origin,
cancer stem cells, and targeted therapies. Stem Cells Int.
2016:36317642016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhao X, Sun S, Xu J, Luo Y, Xin Y and Wang
Y: MicroRNA-152 inhibits cell proliferation of osteosarcoma by
directly targeting Wnt/β-catenin signaling pathway in a
DKK1-dependent manner. Oncol Rep. 40:767–774. 2018.PubMed/NCBI
|
|
4
|
He R, Wu JX, Zhang Y, Chen H and Yang L:
LncRNA LINC00628 overexpression inhibits the growth and invasion
through regulating PI3K/Akt signaling pathway in osteosarcoma. Eur
Rev Med Pharmaco Sci. 22:5857–5866. 2018.
|
|
5
|
Nie WB, Zhao LM, Guo R, Wang MX and Ye FG:
Circular RNA circ-NT5C2 acts as a potential novel biomarker for
prognosis of osteosarcoma. Eur Rev Med Pharmaco Sci. 22:6239–6244.
2018.
|
|
6
|
Zuo DQ, Shogren KL, Zang J, Jewison DE,
Waletzki BE, Miller AL II, Okuno SH, Cai Z, Yaszemski MJ and Maran
A: Inhibition of STAT3 blocks protein synthesis and tumor
metastasis in osteosarcoma cells. J Exp Clin Canc Res. 37:2442018.
View Article : Google Scholar
|
|
7
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tabak SA, Khalifa SE and Fathy Y: HER-2
Immunohistochemical Expression in Bone Sarcomas: A New hope for
patients with osteosarcoma. Open Access Maced J Med Sci.
6:1555–1560. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Meazza C and Scanagatta P: Metastatic
osteosarcoma: A challenging multidisciplinary treatment. Expert Rev
Anticancer Ther. 16:543–556. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhou XS, Paredes JA, Krishnan S, Curbo S
and Karlsson A: The mitochondrial carrier SLC25A10 regulates cancer
cell growth. Oncotarget. 6:9271–9283. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhao Q, Zhou XS, Curbo S and Karlsson A:
Metformin downregulates the mitochondrial carrier SLC25A10 in a
glucose dependent manner. Biochem Pharmacol. 156:444–450. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mizuarai S, Miki S, Araki H, Takahashi K
and Kotani H: Identification of dicarboxylate carrier Slc25a10 as
malate transporter in de novo fatty acid synthesis. J Biol Chem.
280:32434–32441. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hlouschek J, Ritter V, Wirsdorfer F, Klein
D, Jendrossek V and Matschke J: Targeting SLC25A10 alleviates
improved antioxidant capacity and associated radioresistance of
cancer cells induced by chronic-cycling hypoxia. Cancer Lett.
439:24–38. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kulyte A, Ehrlund A, Arner P and Dahlman
I: Global transcriptome profiling identifies KLF15 and SLC25A10 as
modifiers of adipocytes insulin sensitivity in obese women. PLoS
One. 12:e01784852017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huypens P, Pillai R, Sheinin T, Schaefer
S, Huang M, Odegaard ML, Ronnebaum SM, Wettig SD and Joseph JW: The
dicarboxylate carrier plays a role in mitochondrial malate
transport and in the regulation of glucose-stimulated insulin
secretion from rat pancreatic beta cells. Diabetologia. 54:135–145.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin Y, Berg AH, Iyengar P, Lam TK, Giacca
A, Combs TP, Rajala MW, Du X, Rollman B, Li W, et al: The
hyperglycemia-induced inflammatory response in adipocytes: The role
of reactive oxygen species. J Biol Chem. 280:4617–4626. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lockwood WW, Stack D, Morris T, Grehan D,
O'Keane C, Stewart GL, Cumiskey J, Lam WL, Squire JA, Thomas DM and
O'Sullivan MJ: Cyclin E1 is amplified and overexpressed in
osteosarcoma. J Mol Diagn. 13:289–296. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao ZM, Yost SE, Hutchinson KE, Li SM,
Yuan YC, Noorbakhsh J, Liu Z, Warden C, Johnson RM, Wu X, et al:
CCNE1 amplification is associated with poor prognosis in patients
with triple negative breast cancer. BMC Cancer. 19:962019.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sang Y, Zhang R, Sun L, Chen KK, Li SW,
Xiong L, Peng Y, Zeng L and Huang G: MORF4L1 suppresses cell
proliferation, migration and invasion by increasing p21 and
E-cadherin expression in nasopharyngeal carcinoma. Oncol Lett.
17:294–302. 2019.PubMed/NCBI
|
|
20
|
Guo Q, Xiong Y, Song Y, Hua K and Gao S:
ARHGAP17 suppresses tumor progression and up-regulates P21 and P27
expression via inhibiting PI3K/AKT signaling pathway in cervical
cancer. Gene. 692:9–16. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Z, Tao Y, Wang X, Jiang P, Li J, Peng
M, Zhang X, Chen K, Liu H, Zhen P, et al: Tumor-secreted exosomal
miR-222 promotes tumor progression via regulating P27 Expression
and Re-localization in pancreatic cancer. Cell Physiol Biochem.
51:610–629. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen CY, Lei J, Zheng Q, Tan S, Ding KS
and Yu CJ: Poly(rC) binding protein 2 (PCBP2) promotes the
viability of human gastric cancer cells by regulating CDK2. FEBS
Open Bio. 8:764–773. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen C, Zheng Q, Kang W and Yu C: Long
non-coding RNA LINC00472 suppresses hepatocellular carcinoma cell
proliferation, migration and invasion through miR-93-5p/PDCD4
pathway. Clin Res Hepatol Gastroenterol. 43:436–445. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu X, Cai ZD, Lou LM and Zhu YB:
Expressions of p53, c-MYC, BCL-2 and apoptotic index in human
osteosarcoma and their correlations with prognosis of patients.
Cancer Epidemiol. 36:212–216. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cao W, Fang L, Teng S, Chen H and Liu T:
MicroRNA-466 inhibits osteosarcoma cell proliferation and induces
apoptosis by targeting CCND1. Exp Ther Med. 16:5117–5122.
2018.PubMed/NCBI
|
|
26
|
Wang J, Xu G, Shen F and Kang Y: miR-132
targeting cyclin E1 suppresses cell proliferation in osteosarcoma
cells. Tumour Biol. 35:4859–4865. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu Q, Geng P, Shi L, Wang Q and Wang P:
miR-29 promotes osteosarcoma cell proliferation and migration by
targeting PTEN. Oncol Lett. 17:883–890. 2019.PubMed/NCBI
|
|
28
|
Zhao R, He H, Zhu Y, Wan J, Li Y, Gao S
and Zhang C: MiR-204/14-3-3ζ axis regulates osteosarcoma cell
proliferation through SATA3 pathway. Pharmazie. 72:593–598.
2017.PubMed/NCBI
|
|
29
|
Wang J, Wang G, Li B, Qiu C and He M:
miR-141-3p is a key negative regulator of the EGFR pathway in
osteosarcoma. Onco Targets Ther. 11:4461–4478. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lv H, Gao G, Zhang L and Sun Y: Polo-like
kinase 3 inhibits osteosarcoma cell proliferation and tumorigenesis
via cooperative interaction with p21. Mol Med Rep. 12:6789–6796.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang F and Peng H: LncRNA-ANCR regulates
the cell growth of osteosarcoma by interacting with EZH2 and
affecting the expression of p21 and p27. J Orthop Surg Res.
12:1032017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ghosh T, Varshney A, Kumar P, Kaur M,
Kumar V, Shekhar R, Devi R, Priyanka P, Khan MM and Saxena S:
MicroRNA-874-mediated inhibition of the major G1/S phase
cyclin, CCNE1, is lost in osteosarcomas. J Biol Chem.
292:21264–21281. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shukla K, Sharma AK, Ward A, Will R,
Hielscher T, Balwierz A, Breunig C, Münstermann E, König R,
Keklikoglou I and Wiemann S: MicroRNA-30c-2-3p negatively regulates
NF-κB signaling and cell cycle progression through downregulation
of TRADD and CCNE1 in breast cancer. Mol Oncol. 9:1106–1119. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yao Y, Luo J, Sun Q, Xu T, Sun S, Chen M,
Lin X, Qian Q, Zhang Y, Cao L, et al: HOXC13 promotes proliferation
of lung adenocarcinoma via modulation of CCND1 and CCNE1. Am J
Cancer Res. 7:1820–1834. 2017.PubMed/NCBI
|
|
35
|
Zhang Y, Peng Z, Zhao YS and Chen L:
microRNA-25 inhibits cell apoptosis of human gastric adenocarcinoma
cell line AGS via regulating CCNE1 and MYC. Med Sci Monitor.
22:1415–1420. 2016. View Article : Google Scholar
|
|
36
|
Zhang X, Hu SJ, Zhang X, Wang L, Zhang X,
Yan B, Zhao J, Yang A and Zhang R: MicroRNA-7 arrests cell cycle in
G1 phase by directly targeting CCNE1 in human hepatocellular
carcinoma cells. Biochem Biophys Res Commun. 443:1078–1084. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fujii R, Osaka E, Sato K and Tokuhashi Y:
MiR-1 suppresses proliferation of osteosarcoma cells by
Up-regulating p21 via PAX3. Cancer Genom Proteom. 16:71–79. 2019.
View Article : Google Scholar
|
|
38
|
Huang J, Deng GR, Liu TM, Chen WZ and Zhou
Y: Long noncoding RNA PCAT-1 acts as an oncogene in osteosarcoma by
reducing p21 levels. Biochem Biophys Res Commun. 495:2622–2629.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ding Y, Wang YC, Chen J, Hu Y, Cao Z, Ren
P and Zhang Y: p21 overexpression sensitizes osteosarcoma U2OS
cells to cisplatin via evoking caspase-3 and Bax/Bcl-2 cascade.
Tumor Biol. 35:3119–3123. 2014. View Article : Google Scholar
|
|
40
|
Li Z, Yu D, Li H, Lv Y and Li S: Long
noncoding RNA UCA1 confers tamoxifen resistance in breast cancer
endocrinotherapy through regulation of the EZH2/p21 axis and the
PI3K/AKT signaling pathway. Int J Oncol. 54:1033–1042.
2019.PubMed/NCBI
|
|
41
|
Guo L, Gu J, Hou S, Liu D, Zhou M, Hua T,
Zhang J, Ge Z and Xu J: Long non-coding RNA DANCR promotes the
progression of non-small-cell lung cancer by inhibiting p21
expression. Onco Targets Ther. 12:135–146. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Liao QD, Zhong D and Chen Q: Protein
expression of Skp2 in osteosarcoma and its relation with prognosis.
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 33:606–611. 2008.(In Chinese).
PubMed/NCBI
|
|
43
|
Hu XH, Zhao ZX, Dai J, Geng DC and Xu YZ:
MicroRNA-221 regulates osteosarcoma cell proliferation, apoptosis,
migration, and invasion by targeting CDKN1B/p27. J Cell Biochem.
120:4665–4674. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Li H, Guan H, Guo Y, Liang W, Liu L, He X,
Ke W, Cao X, Xiao H and Li Y: CITED1 promotes proliferation of
papillary thyroid cancer cells via the regulation of p21 and p27.
Cell Biosci. 8:572018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Vijay K, Sowmya PR, Arathi BP, Shilpa S,
Shwetha HJ, Raju M, Baskaran V and Lakshminarayana R: Low-dose
doxorubicin with carotenoids selectively alters redox status and
upregulates oxidative stress-mediated apoptosis in breast cancer
cells. Food Chem Toxicol. 118:675–690. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhang D, Wang Y, Liang Y, Zhang M, Wei J,
Zheng X, Li F, Meng Y, Zhu NW, Li J, et al: Loss of p27 upregulates
MnSOD in a STAT3-dependent manner, disrupts intracellular redox
activity and enhances cell migration. J Cell Sci. 127:2920–2933.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tang Z, Fang Y and Du R: MicroRNA-107
induces cell cycle arrests by directly targeting cyclin E1 in
ovarian cancer. Biochem Biophys Res Commun. 512:331–337. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yang M, Peng Y, Liu W, Zhou M, Meng Q and
Yuan C: Sirtuin 2 expression suppresses oxidative stress and
senescence of nucleus pulposus cells through inhibition of the
p53/p21 pathway. Biochem Biophys Res Commun. 513:616–622. 2019.
View Article : Google Scholar : PubMed/NCBI
|
